A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis

Alejandro Castellanos, A. Clinton White, Kayode K. Ojo, Rama S R Vidadala, Zhongsheng Zhang, Molly C. Reid, Anna M W Fox, Katelyn R. Keyloun, Kasey Rivas, Ayesha Irani, Sara Dann-Grice, Erkang Fan, Dustin J. Maly, Wesley C. Van Voorhis

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Cryptosporidium parasites infect intestinal cells, causing cryptosporidiosis. Despite its high morbidity and association with stunting in the developing world, current therapies for cryptosporidiosis have limited efficacy. Calcium-dependent protein kinases (CDPKs) are essential enzymes in the biology of protozoan parasites. CDPK1 was cloned from the genome of Cryptosporidium parvum, and potent and specific inhibitors have been developed based on structural studies. In this study, we evaluated the anti-Cryptosporidium activity of a novel CDPK1 inhibitor, 1294, and demonstrated that 1294 significantly reduces parasite infection in vitro, with a half maximal effective concentration of 100 nM. Pharmacokinetic studies revealed that 1294 is well absorbed, with a half-life supporting daily administration. Oral therapy with 1294 eliminated Cryptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the parasites did not recur in these immunosuppressed mice. Mice treated with 1294 had less epithelial damage, corresponding to less apoptosis. Thus, 1294 is an important lead for the development of drugs for treatment of cryptosporidiosis.

Original languageEnglish (US)
Pages (from-to)1342-1348
Number of pages7
JournalJournal of Infectious Diseases
Volume208
Issue number8
DOIs
StatePublished - Oct 15 2013

Fingerprint

Cryptosporidiosis
Protein Kinase Inhibitors
Cryptosporidium
Parasites
Growth Disorders
Cryptosporidium parvum
Severe Combined Immunodeficiency
Parasitic Diseases
Half-Life
Pharmacokinetics
Genome
Apoptosis
Morbidity
calcium-dependent protein kinase
Lead
Enzymes
Therapeutics
Pharmaceutical Preparations

Keywords

  • antiparasitic
  • bumped kinase inhibitor
  • Calcium-dependant Protein kinase
  • CpCDPK-1
  • cryptosporidiosis
  • Cryptosporidium parvum

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. / Castellanos, Alejandro; White, A. Clinton; Ojo, Kayode K.; Vidadala, Rama S R; Zhang, Zhongsheng; Reid, Molly C.; Fox, Anna M W; Keyloun, Katelyn R.; Rivas, Kasey; Irani, Ayesha; Dann-Grice, Sara; Fan, Erkang; Maly, Dustin J.; Van Voorhis, Wesley C.

In: Journal of Infectious Diseases, Vol. 208, No. 8, 15.10.2013, p. 1342-1348.

Research output: Contribution to journalArticle

Castellanos, A, White, AC, Ojo, KK, Vidadala, RSR, Zhang, Z, Reid, MC, Fox, AMW, Keyloun, KR, Rivas, K, Irani, A, Dann-Grice, S, Fan, E, Maly, DJ & Van Voorhis, WC 2013, 'A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis', Journal of Infectious Diseases, vol. 208, no. 8, pp. 1342-1348. https://doi.org/10.1093/infdis/jit327
Castellanos, Alejandro ; White, A. Clinton ; Ojo, Kayode K. ; Vidadala, Rama S R ; Zhang, Zhongsheng ; Reid, Molly C. ; Fox, Anna M W ; Keyloun, Katelyn R. ; Rivas, Kasey ; Irani, Ayesha ; Dann-Grice, Sara ; Fan, Erkang ; Maly, Dustin J. ; Van Voorhis, Wesley C. / A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. In: Journal of Infectious Diseases. 2013 ; Vol. 208, No. 8. pp. 1342-1348.
@article{a25f3811c63b4cecab9a7416f54088e1,
title = "A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis",
abstract = "Cryptosporidium parasites infect intestinal cells, causing cryptosporidiosis. Despite its high morbidity and association with stunting in the developing world, current therapies for cryptosporidiosis have limited efficacy. Calcium-dependent protein kinases (CDPKs) are essential enzymes in the biology of protozoan parasites. CDPK1 was cloned from the genome of Cryptosporidium parvum, and potent and specific inhibitors have been developed based on structural studies. In this study, we evaluated the anti-Cryptosporidium activity of a novel CDPK1 inhibitor, 1294, and demonstrated that 1294 significantly reduces parasite infection in vitro, with a half maximal effective concentration of 100 nM. Pharmacokinetic studies revealed that 1294 is well absorbed, with a half-life supporting daily administration. Oral therapy with 1294 eliminated Cryptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the parasites did not recur in these immunosuppressed mice. Mice treated with 1294 had less epithelial damage, corresponding to less apoptosis. Thus, 1294 is an important lead for the development of drugs for treatment of cryptosporidiosis.",
keywords = "antiparasitic, bumped kinase inhibitor, Calcium-dependant Protein kinase, CpCDPK-1, cryptosporidiosis, Cryptosporidium parvum",
author = "Alejandro Castellanos and White, {A. Clinton} and Ojo, {Kayode K.} and Vidadala, {Rama S R} and Zhongsheng Zhang and Reid, {Molly C.} and Fox, {Anna M W} and Keyloun, {Katelyn R.} and Kasey Rivas and Ayesha Irani and Sara Dann-Grice and Erkang Fan and Maly, {Dustin J.} and {Van Voorhis}, {Wesley C.}",
year = "2013",
month = "10",
day = "15",
doi = "10.1093/infdis/jit327",
language = "English (US)",
volume = "208",
pages = "1342--1348",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis

AU - Castellanos, Alejandro

AU - White, A. Clinton

AU - Ojo, Kayode K.

AU - Vidadala, Rama S R

AU - Zhang, Zhongsheng

AU - Reid, Molly C.

AU - Fox, Anna M W

AU - Keyloun, Katelyn R.

AU - Rivas, Kasey

AU - Irani, Ayesha

AU - Dann-Grice, Sara

AU - Fan, Erkang

AU - Maly, Dustin J.

AU - Van Voorhis, Wesley C.

PY - 2013/10/15

Y1 - 2013/10/15

N2 - Cryptosporidium parasites infect intestinal cells, causing cryptosporidiosis. Despite its high morbidity and association with stunting in the developing world, current therapies for cryptosporidiosis have limited efficacy. Calcium-dependent protein kinases (CDPKs) are essential enzymes in the biology of protozoan parasites. CDPK1 was cloned from the genome of Cryptosporidium parvum, and potent and specific inhibitors have been developed based on structural studies. In this study, we evaluated the anti-Cryptosporidium activity of a novel CDPK1 inhibitor, 1294, and demonstrated that 1294 significantly reduces parasite infection in vitro, with a half maximal effective concentration of 100 nM. Pharmacokinetic studies revealed that 1294 is well absorbed, with a half-life supporting daily administration. Oral therapy with 1294 eliminated Cryptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the parasites did not recur in these immunosuppressed mice. Mice treated with 1294 had less epithelial damage, corresponding to less apoptosis. Thus, 1294 is an important lead for the development of drugs for treatment of cryptosporidiosis.

AB - Cryptosporidium parasites infect intestinal cells, causing cryptosporidiosis. Despite its high morbidity and association with stunting in the developing world, current therapies for cryptosporidiosis have limited efficacy. Calcium-dependent protein kinases (CDPKs) are essential enzymes in the biology of protozoan parasites. CDPK1 was cloned from the genome of Cryptosporidium parvum, and potent and specific inhibitors have been developed based on structural studies. In this study, we evaluated the anti-Cryptosporidium activity of a novel CDPK1 inhibitor, 1294, and demonstrated that 1294 significantly reduces parasite infection in vitro, with a half maximal effective concentration of 100 nM. Pharmacokinetic studies revealed that 1294 is well absorbed, with a half-life supporting daily administration. Oral therapy with 1294 eliminated Cryptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the parasites did not recur in these immunosuppressed mice. Mice treated with 1294 had less epithelial damage, corresponding to less apoptosis. Thus, 1294 is an important lead for the development of drugs for treatment of cryptosporidiosis.

KW - antiparasitic

KW - bumped kinase inhibitor

KW - Calcium-dependant Protein kinase

KW - CpCDPK-1

KW - cryptosporidiosis

KW - Cryptosporidium parvum

UR - http://www.scopus.com/inward/record.url?scp=84885026864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885026864&partnerID=8YFLogxK

U2 - 10.1093/infdis/jit327

DO - 10.1093/infdis/jit327

M3 - Article

VL - 208

SP - 1342

EP - 1348

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -